Join to view full profile
Rahway -Princeton, NJ 08540
Phone+1 801-865-2334
Dr. Grossmann is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2007 - 2009
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2006 - 2007- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2004 - 2006
Oregon Health and Science University School of MedicineClass of 2004
Certifications & Licensure
OR State Medical License 2023 - 2027
UT State Medical License 2007 - 2024
FL State Medical License 2018 - 2020
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.Megan Othus, Thach-Giao Truong, Elad Sharon, Kari Kendra, Kenneth Grossmann
JCO Oncology Practice. 2026-06-23 - 2 citationsNeoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, Siwen Hu-Lieskovan, Katie M Campbell
Nature Cancer. 2026-02-01 - 49 citationsRandomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, Jennifer R Wortman, Elizabeth M Burton
Cancer Discovery. 2024-07-01
Journal Articles
- Prognostic Gene Expression Profiling in Cutaneous MelanomaDouglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Kari L..., JAMA Dermatology
Authored Content
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Press Mentions
Adjuvant Pembrolizumab Improves RFS, Not OS, in Resected High-Risk MelanomaJune 8th, 2021- SWOG Researchers to Present Practice-Changing Research at Virtual ASCO 2021June 1st, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
